• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Verve Therapeutics Inc.

    10/16/24 1:06:10 PM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VERV alert in real time by email
    SC 13G 1 Verve_Therapeutics_Inc.htm SCHEDULE 13G Amendment No. 15

     

      SECURITIES AND EXCHANGE COMMISSION  
      Washington, D.C. 20549  
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. )*
     

    VERVE THERAPEUTICS INC

    (Name of Issuer)
     

    COMMON STOCK

    (Title of Class of Securities)
     

    92539P101

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ý Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 5 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     

    92539P101 13G Page 2 of 5 Pages

     

    1

    NAME OF REPORTING PERSON

    STATE STREET CORPORATION

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: 04-2456637

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    MA

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    4,060,913

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    4,253,217

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,253,217.00

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.0%

    12

    TYPE OF REPORTING PERSON

    HC

             

     

     

     

    92539P101 13G Page 3 of 5 Pages

     

    Item 1(a). NAME OF ISSUER
       
      VERVE THERAPEUTICS INC

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES
       
      500 TECHNOLOGY SQ STE 901 CAMBRIDGE MA 02139 UNITED STATES

     

    Item 2(a). NAME OF PERSON FILING
       
     

    STATE STREET CORPORATION

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
       
      ONE CONGRESS STREET, SUITE 1, BOSTON MA 02114, UNITED STATES

     

    Item 2(c). CITIZENSHIP
       
      MA

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
       
      COMMON STOCK

     

    Item 2(e). CUSIP NUMBER
       
      92539P101

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§240.13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

    STATE STREET CORPORATION (a) Broker or dealer registered under Section 15 of the Act;
      (b) Bank as defined in Section 3(a)(6) of the Act;
      (c) Insurance company as defined in Section 3(a)(19) of the Act;
      (d) Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
      (f)

    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

      (g) X

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

      (h)

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i)

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
      (k) Group, in accordance with §240.13d-1(b)(1)(ii)(K).
      If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

     

    92539P101 13G Page 4 of 5 Pages

     

    Item 4. OWNERSHIP
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
      (a) Amount beneficially owned: 4,253,217.00  
      (b) Percent of class: 5.0%  
      (c) Number of shares as to which the person has:    
             
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote 4,060,913
        (iii) Sole power to dispose or to direct the disposition of 0
        (iv) Shared power to dispose or to direct the disposition of 4,253,217
             
      Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following
      ¨
      Instruction: Dissolution of a group requires a response to this item.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
       
      NOT APPLICABLE

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
       
      SSGA FUNDS MANAGEMENT, INC. (IA) STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA) STATE STREET GLOBAL ADVISORS LIMITED (IA) STATE STREET GLOBAL ADVISORS TRUST COMPANY (IA) STATE STREET GLOBAL ADVISORS, LTD. (IA)

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
       
      NOT APPLICABLE

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
       
      NOT APPLICABLE

     

    Item 10. CERTIFICATION

     

      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11
       

     

     

     

    92539P101 13G Page 5 of 5 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: October 14, 2024

     

       
         
         
        ELIZABETH SCHAEFER, SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
         
         

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties for whom copies are to be sent.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

     

    Get the next $VERV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VERV

    DatePrice TargetRatingAnalyst
    4/15/2025Neutral → Overweight
    Cantor Fitzgerald
    4/8/2024$15.00Buy
    H.C. Wainwright
    4/13/2023$29.00Buy
    Canaccord Genuity
    2/1/2023$21.00Neutral
    Cantor Fitzgerald
    12/15/2022$13.00Sell
    Goldman
    10/6/2022$48.00Neutral
    Credit Suisse
    8/25/2022$32.00 → $56.00Hold → Buy
    Stifel
    6/17/2022$48.00Outperform
    BMO Capital Markets
    More analyst ratings

    $VERV
    SEC Filings

    See more
    • SEC Form EFFECT filed by Verve Therapeutics Inc.

      EFFECT - Verve Therapeutics, Inc. (0001840574) (Filer)

      5/15/25 12:15:05 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Verve Therapeutics Inc.

      10-Q - Verve Therapeutics, Inc. (0001840574) (Filer)

      5/14/25 7:30:21 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verve Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Verve Therapeutics, Inc. (0001840574) (Filer)

      5/14/25 7:15:09 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Administrative Officer Nickerson Joan converted options into 9,315 shares and sold $11,525 worth of shares (2,777 units at $4.15), increasing direct ownership by 60% to 17,420 units (SEC Form 4)

      4 - Verve Therapeutics, Inc. (0001840574) (Issuer)

      4/3/25 5:00:17 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Ashe Andrew D. converted options into 9,000 shares and sold $11,126 worth of shares (2,681 units at $4.15), increasing direct ownership by 2% to 348,828 units (SEC Form 4)

      4 - Verve Therapeutics, Inc. (0001840574) (Issuer)

      4/3/25 5:00:14 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Kathiresan Sekar converted options into 33,000 shares and sold $40,761 worth of shares (9,822 units at $4.15), increasing direct ownership by 7% to 346,686 units (SEC Form 4)

      4 - Verve Therapeutics, Inc. (0001840574) (Issuer)

      4/3/25 5:00:19 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ashe Andrew D. bought $475,760 worth of shares (76,000 units at $6.26), increasing direct ownership by 29% to 342,509 units (SEC Form 4)

      4 - Verve Therapeutics, Inc. (0001840574) (Issuer)

      5/15/24 5:30:07 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Yeshwant Krishna bought $18,000,000 worth of shares (1,800,000 units at $10.00) (SEC Form 4)

      4 - Verve Therapeutics, Inc. (0001840574) (Issuer)

      12/5/23 4:30:09 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Verve Therapeutics Inc.

      SC 13G - Verve Therapeutics, Inc. (0001840574) (Subject)

      11/18/24 5:23:52 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Verve Therapeutics Inc.

      SC 13G/A - Verve Therapeutics, Inc. (0001840574) (Subject)

      11/12/24 5:52:40 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Verve Therapeutics Inc.

      SC 13G/A - Verve Therapeutics, Inc. (0001840574) (Subject)

      11/4/24 1:52:43 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Verve Therapeutics upgraded by Cantor Fitzgerald

      Cantor Fitzgerald upgraded Verve Therapeutics from Neutral to Overweight

      4/15/25 8:57:58 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Verve Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Verve Therapeutics with a rating of Buy and set a new price target of $15.00

      4/8/24 8:03:41 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Verve Therapeutics with a new price target

      Canaccord Genuity initiated coverage of Verve Therapeutics with a rating of Buy and set a new price target of $29.00

      4/13/23 7:37:44 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERV
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $VERV
    Leadership Updates

    Live Leadership Updates

    See more
    • Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results

      Reported positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 demonstrating dose-dependent decreases in blood LDL-C and PCSK9 Mean reduction in LDL-C of 53%, with a maximum reduction of 69%, observed after a single infusion of VERVE-102 in the 0.6 mg/kg dose cohort in the Heart-2 clinical trial Pulse-1 Phase 1b clinical trial of VERVE-201 targeting ANGPTL3 continues to progress with a program update expected in the second half of 2025 Cash, cash equivalents, and marketable securities of approximately $500 million; cash runway into mid-2027 BOSTON , May 14, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic med

      5/14/25 7:00:00 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

      BOSTON , May 02, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on April 30, 2025, the company granted equity awards to seven new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received stock options to purchase an aggregate of 134,860 shares of the company's common stock and an aggregate of 65,398 restricted stock units (RSUs). The options have an exercise price of $5.67 per share, which is equa

      5/2/25 4:05:00 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

      Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort VERVE-102 was well-tolerated with no treatment-related serious adverse events and no clinically significant changes in ALT or platelets observed at any dose level among 14 participants VERVE-102 utilizes a proprietary GalNAc-LNP which has demonstrated a potentially best-in-class safety profile In the second half of 2025, Verve expects to report final Heart-2 dose escalation data, dose the first patient in a Phase 2 clinical trial for VERVE-102, and receive a decision from Eli Lilly and Company for th

      4/14/25 7:00:00 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

      WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight

      4/1/25 7:00:00 AM ET
      $ABOS
      $CLYM
      $LENZ
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer

      BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Frederick "Fred" T. Fiedorek, M.D., as chief medical officer (CMO). Andrew Bellinger, M.D., Ph.D., the current chief scientific officer (CSO) and CMO, will transition to the role of CSO. "We are excited by the continued expansion of the Verve team and the execution of a plan to become a multi-product clinical-stage company," said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve. "Our heart-1 clinical trial is well underway, wi

      9/18/23 6:30:00 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verve Therapeutics Appoints Experienced Biotechnology Executive, Alexander G. "Bo" Cumbo, to its Board of Directors

      CAMBRIDGE, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Alexander G. "Bo" Cumbo, chief executive officer and president of AavantiBio, Inc., has joined the company's board of directors. "Bo is a highly experienced industry executive with a well-established track record of leading pharmaceutical and life sciences companies through critical processes in drug development and commercial execution," said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve. "As we focus on continued execution of our regulatory

      6/13/22 6:30:00 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERV
    Financials

    Live finance-specific insights

    See more
    • Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

      Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort VERVE-102 was well-tolerated with no treatment-related serious adverse events and no clinically significant changes in ALT or platelets observed at any dose level among 14 participants VERVE-102 utilizes a proprietary GalNAc-LNP which has demonstrated a potentially best-in-class safety profile In the second half of 2025, Verve expects to report final Heart-2 dose escalation data, dose the first patient in a Phase 2 clinical trial for VERVE-102, and receive a decision from Eli Lilly and Company for th

      4/14/25 7:00:00 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia

      LDL-C Reductions Up to 55% and Blood PCSK9 Protein Reductions Up to 84% Observed After a Single Infusion of VERVE-101 at Potentially Therapeutic Doses Safety Profile Supports Continued Development of VERVE-101 Enrollment Ongoing in the 0.45 mg/kg and 0.6 mg/kg Cohorts with Plans to Initiate Expansion Cohort in 2024 Company to Host Conference Call and Webcast Today at 6:30 p.m. ET BOSTON, Nov. 12, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced first human proof-of-concept data for in vivo base editing from the ongoing hear

      11/12/23 3:30:00 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care